MedTrace Logo

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

NCT01071928 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-19

No results posted yet for this study

Summary

The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as second-line chemotherapy in patients with advanced urothelial carcinoma.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1

DRUG

ASA404

ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1

Sponsors & Collaborators

Principal Investigators

  • Matthew Galsky, M.D. · Hoosier Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01071928 on ClinicalTrials.gov